Geron to Present at Three Key Investor Conferences in March
Event summary
- Geron management to present at TD Cowen Healthcare Conference on March 2.
- Fireside chat scheduled at Barclays Global Healthcare Conference on March 10.
- In-person meetings planned at Leerink Partners Global Healthcare Conference on March 11.
- Live and archived webcasts available via Geron’s investor relations page.
The big picture
Geron’s participation in three major investor conferences underscores its focus on engaging with the financial community amid a pivotal phase for its telomerase inhibitor, RYTELO. The company’s strategic emphasis on blood cancer treatments aligns with broader industry trends toward targeted therapies, particularly in hematologic malignancies. With RYTELO approved in key markets, Geron’s ability to articulate its growth trajectory will be critical for maintaining investor support.
What we're watching
- Clinical Pipeline
- How Geron’s Phase 3 trial progress in JAK-inhibitor R/R MF will be addressed during presentations.
- Market Positioning
- Whether Geron can leverage RYTELO’s approvals to strengthen its blood cancer portfolio.
- Investor Sentiment
- The pace at which Geron can convert conference momentum into tangible investor confidence.
Related topics